RESUMEN
Among the new contaminants relevant for environment, one of the most significant roles is played by pharmaceuticals like antibiotic products for either human or veterinary use. Their presence could cause serious damage to bacteria and microfauna, like nematodes. Within the widely investigated nematodes, very little is known about the interaction between antibiotics and entomopathogenic nematodes (EPN). EPNs have been used for biological control of crops, due to their ability to penetrate arthropod pests and kill their hosts thanks to a complex symbiotic mechanism with specific gram-negative bacteria. Tetracycline is an antibiotic used in human and veterinary medicine, both for therapeutic purposes and for the growth of livestock. Since its action against gram-negative bacteria is documented, we verified in this study the survival, growth and pathogenicity of two species of EPNs, Steinernema vulcanicum and S. feltiae. All tests were performed with tetracycline in 1% ethanol solution and up to 300 mg/L. Apparently, this incubation did not harm the vitality of EPNs. Both S. vulcanicum as S. feltiae recovered their vitality and entomopathogenic ability after 48 h. Moreover, the latter EPN species did not grow nor reproduce in the hemolymph of the Greater Wax Moth, Galleria mellonella, and their endosymbionts did not grow on MacConkey Agar. Our results suggest that the first EPN species has always retained all its abilities and that endosymbionts have acquired resistance to tetracycline, while experiments with the second EPN species provided some contrasting results in time that will require further investigations.
Asunto(s)
Mariposas Nocturnas , Rabdítidos , Animales , Antibacterianos/toxicidad , Bacterias , Humanos , TetraciclinasRESUMEN
Loss of heterozygosity data from familial tumors suggest that BRCA1, a gene that confers susceptibility to ovarian and early-onset breast cancer, encodes a tumor suppressor. The BRCA1 region is also subject to allelic loss in sporadic breast and ovarian cancers, an indication that BRCA1 mutations may occur somatically in these tumors. The BRCA1 coding region was examined for mutations in primary breast and ovarian tumors that show allele loss at the BRCA1 locus. Mutations were detected in 3 of 32 breast and 1 of 12 ovarian carcinomas; all four mutations were germline alterations and occurred in early-onset cancers. These results suggest that mutation of BRCA1 may not be critical in the development of the majority of breast and ovarian cancers that arise in the absence of a mutant germline allele.
Asunto(s)
Neoplasias de la Mama/genética , Genes Supresores de Tumor , Mutación de Línea Germinal , Proteínas de Neoplasias/genética , Neoplasias Ováricas/genética , Factores de Transcripción/genética , Adulto , Edad de Inicio , Alelos , Proteína BRCA1 , Secuencia de Bases , Cromosomas Humanos Par 17 , Femenino , Predisposición Genética a la Enfermedad , Heterocigoto , Humanos , Persona de Mediana Edad , Datos de Secuencia MolecularRESUMEN
Inherited BRCA2 mutations confer profound susceptibility to human breast and ovarian cancer. The rat and mouse Brca2 homologues share 58% and 59% identity (72% similarity), respectively, with the human BRCA2 protein. The Brca2 proteins also share a potential nuclear localization signal (human codons 3263-3269) and a highly conserved large carboxyl region (77% identity, 86% similarity between human and rodents) that may represent important functional domains. At least six of eight previously described BRC repeats have been highly conserved in rats and mice. Expression studies demonstrate an 11-12 Kb transcript with rodent tissue-specific patterns of expression consistent with human BRCA2. These results will facilitate studies of Brca2 function during normal and neoplastic development.
Asunto(s)
Proteínas de Neoplasias/genética , Factores de Transcripción/genética , Secuencia de Aminoácidos , Animales , Proteína BRCA2 , Northern Blotting , Secuencia de Consenso , Humanos , Ratones , Datos de Secuencia Molecular , Proteínas de Neoplasias/biosíntesis , Polimorfismo Genético , Ratas , Alineación de Secuencia , Distribución Tisular , Factores de Transcripción/biosíntesisRESUMEN
The p16INK4a (alpha and beta form) and p15INK4b genes were analysed for homozygous deletion, hypermethylation and point mutation in B6C3F1 mouse lymphomas induced by 2',3'-dideoxycytidine or 1,3-butadiene. Although the p16INK4a-alpha gene appeared normal in DNA from 2',3'-dideoxycytidine-induced lymphomas, Southern analyses revealed homozygous deletions or rearrangements of the p16INK4a-beta and/or p15INK4b genes in four of 16 tumours. Surprisingly, two of these lymphomas showed exclusive deletions of the p16INK4a EIbeta exon. The p15INK4b promoter region was hypermethylated in two additional 2',3'-dideoxycytidine-induced lymphomas. In contrast, homozygous deletions spanning the p16INK4a and p15INK4b loci were observed in only two of 31 1,3-butadiene-induced tumours. Thus, these cyclin dependent kinase inhibitor genes may play a significant role in chemically induced mouse lymphomas and support the contention of tumour suppressor activity for the p19ARF protein encoded by the p16INK4a-beta gene. Different genetic pathways may be involved in the development of these chemically induced tumours since we have previously shown that mutations in p53 and ras genes are common in 1,3-butadiene- but not 2',3'-dideoxycytidine-induced lymphomas.
Asunto(s)
Butadienos/farmacología , Carcinógenos/farmacología , Proteínas Portadoras/genética , Proteínas de Ciclo Celular , Inhibidor p16 de la Quinasa Dependiente de Ciclina/genética , Linfoma/genética , Neoplasias Experimentales/genética , Proteínas Supresoras de Tumor , Zalcitabina/farmacología , Animales , Islas de CpG , Inhibidor p15 de las Quinasas Dependientes de la Ciclina , Metilación de ADN , ADN de Neoplasias , Homocigoto , Linfoma/inducido químicamente , Ratones , Ratones Endogámicos C57BL , Mutación Puntual , Polimorfismo Conformacional Retorcido-Simple , Regiones Promotoras Genéticas , Análisis de Secuencia de ADN/métodosRESUMEN
The genes of murine cyclin D-dependent kinase inhibitors, p15INK4b and p16INK4a, are located in a region of chromosome 4 where overlapping deletions were found in lung adenocarcinomas. The p16INK4a gene uniquely consists of alternative first exons (E1alpha and E1beta), which are spliced to exon 2 in alternative reading frames to either encode p16INK4a (alpha form) or another potential tumor suppressor, p19ARF (beta form). We examined 99 lung adenocarcinomas of C3H/HeJ x A/J F1(C3AF1) and A/J x C3H/HeJ F1(AC3F1) mouse hybrids and 18 (13 metastatic, 5 nonmetastatic) tumorigenic mouse lung epithelial cell lines for p15INK4b and p16INK4a gene inactivation. Homozygous codeletion occurred in eight of the 13 (62%) metastatic, four of the five (80%) nonmetastatic cell lines, but in only six of 99 (6%) adenocarcinomas. Neither p15INK4b nor p16INK4a gene was individually deleted in any of the tumors or cell lines, and all deletions of the p16INK4a gene extended into exon 2, which would be expected to disrupt the functions of both p16INK4a and p19ARF. We also detected no intragenic mutations of either gene in 44 tumors that displayed loss of heterozygosity at the p16INK4a locus or in any of the cell lines. Transcript levels of p16INK4a-alpha, p16INK4a-beta and p15INK4b also were examined in each of the cell lines that retained copies of these genes. Whereas an immortal mouse lung epithelial cell line (E10) and two metastatic tumor cell lines (LM1 and E9) expressed p16INK4a-beta and p15INK4b mRNA, the alpha transcript of p16INK4a was detected in only the LM1 cell line. These results suggest that both p15INK4b and p16INK4a (alpha and beta) are targets of inactivation in mouse lung tumorigenesis.
Asunto(s)
Proteínas Portadoras/genética , Proteínas de Ciclo Celular , Homocigoto , Neoplasias Pulmonares/genética , Proteínas Supresoras de Tumor , Adenocarcinoma/genética , Adenocarcinoma/metabolismo , Animales , Northern Blotting , Proteínas Portadoras/biosíntesis , Deleción Cromosómica , Inhibidor p15 de las Quinasas Dependientes de la Ciclina , Inhibidor p16 de la Quinasa Dependiente de Ciclina , Eliminación de Gen , Regulación Neoplásica de la Expresión Génica , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/patología , Ratones , Ratones Endogámicos , Metástasis de la Neoplasia/genética , Reacción en Cadena de la Polimerasa/métodos , Células Tumorales CultivadasRESUMEN
Platelets from diabetic subjects with circulating immune complexes (CIC) synthesized greater amounts of thromboxane than did platelets from CIC-negative patients or controls. In view of the known action of CIC on platelet function, a relationship between these two factors may be suggested in the initiation and progression of microangiopathy in diabetes.
Asunto(s)
Complejo Antígeno-Anticuerpo/análisis , Plaquetas/enzimología , Diabetes Mellitus Tipo 1/inmunología , Tromboxano B2/biosíntesis , Tromboxanos/biosíntesis , Anticuerpos Antiidiotipos/análisis , Niño , Complemento C3/inmunología , Diabetes Mellitus Tipo 1/sangre , Diabetes Mellitus Tipo 1/enzimología , Femenino , Humanos , Inmunoglobulina G/inmunología , Anticuerpos Insulínicos/análisis , MasculinoRESUMEN
AIM: The aim of the study was to evaluate endothelial function and intima media thickness (IMT) in relation to cardiovascular risk factors (RF). METHODS: We enrolled 113 patients, mean age 62 +/- 12 years; patients underwent: anamnesis, physical examination, measurement of body weight and height and blood pressure. Biochemistry variables were also measured: total cholesterol, high- and low-density lipoprotein cholesterol (HDL-C and LDL-C), triglycerides and glycemia. Vascular echography was performed to analyze flow mediated vasodilatation (FMD) at the brachial artery and IMT of the carotid and femoral arteries. RESULTS: Compared with patients without RF, patients with cardiovascular RF showed an impaired FMD (p < 0.05) and higher values of mean carotid IMT (p = 0.03). Age (p < 0.005) and diabetes (p < 0.05) were directly correlated with carotid IMT, while femoral IMT is correlated with age (p < 0.005) and male gender (p < 0.02). Regarding the relationship between endothelial function cardiovascular RF, we showed an inverse linear correlation between systolic blood pressure (p < 0.005), smoking (p < 0.05) and FMD, and concerning biochemical parameters, we founded that total cholesterol (p < 0.05) and LDL-C plasma levels (p < 0.005) were inversely correlated with FMD. Finally, we showed a lower FMD in patients with carotid and femoral IMT in comparison with patients without peripheral atherosclerosis (p = 0.01). CONCLUSIONS: The present data indicate that cardiovascular RF are associated with impaired endothelial function and increased IMT, and that the presence of carotid and femoral IMT is significantly correlated with endothelial dysfunction.
Asunto(s)
Aterosclerosis/epidemiología , Arterias Carótidas/patología , Endotelio Vascular/fisiopatología , Arteria Femoral/patología , Túnica Íntima/patología , Túnica Media/patología , Anciano , Aterosclerosis/patología , Aterosclerosis/fisiopatología , Arteria Braquial/diagnóstico por imagen , Arteria Braquial/patología , Enfermedades Cardiovasculares/epidemiología , Arterias Carótidas/diagnóstico por imagen , Femenino , Arteria Femoral/diagnóstico por imagen , Humanos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Flujo Sanguíneo Regional , Factores de Riesgo , Fumar/epidemiología , Ultrasonografía , VasodilataciónRESUMEN
Topical negative pressure (TNP) has been introduced in complex surgical reconstruction and difficult wound healing, having proven to be effective in both drainage of wound secretions and calling for a new, sterile granulating tissue. In the last 15 years many reports have been focusing on TNP in different surgical specialties (orthopedic surgery in exposed fractures, general surgery in eventration, cardiothoracic surgery in sternal dehiscences, plastic surgery in difficult wounds and pressure sores). The authors report their personal experience being among the first Units to use TNP systematically in Italy.
Asunto(s)
Procedimientos de Cirugía Plástica/instrumentación , Procedimientos de Cirugía Plástica/métodos , Cicatrización de Heridas , Diseño de Equipo , Humanos , Presión , VacioRESUMEN
An increased susceptibility of platelets to aggregation induced by various agents and a higher production of active arachidonate metabolism have been described in type IIa hypercholesterolemia. This study was designed to evaluate whether changes in platelet function could be observed in hypercholesterolemic patients after synvinolin therapy. Administration of synvinolin to 12 type IIa hypercholesterolemic patients for 24 weeks had a lipid lowering effect and resulted in a marked reduction of platelet aggregation and thromboxane formation induced by collagen and arachidonate. Maximum response was achieved at 4-8 weeks and lipid lowering effects at 2 weeks. This finding indicates that platelet changes cannot be explained by a direct effect of synvinolin on platelets, and the antiplatelet response may therefore depend on platelet membrane lipid composition changes, particularly in the platelet cholesterol content of platelet membranes, following substantial reductions of total plasma cholesterol and LDL-cholesterol.
Asunto(s)
Anticolesterolemiantes/farmacología , Hiperlipoproteinemia Tipo II/tratamiento farmacológico , Lovastatina/análogos & derivados , Agregación Plaquetaria/efectos de los fármacos , Tromboxano B2/metabolismo , Anciano , Femenino , Humanos , Lovastatina/farmacología , Lovastatina/uso terapéutico , Masculino , Persona de Mediana Edad , SimvastatinaRESUMEN
A multicenter study was carried out in 130 out-patients to assess the plasma lipid lowering activity of acipimox in type IIa, IIb and IV hyperlipoproteinemia. The study consisted of two periods, an 8-week randomized, double-blind comparison of active drug versus placebo and a 16-week open follow-up with acipimox (400 mg and 250 mg t.i.d., respectively, in type II and IV patients). During the double-blind phase acipimox, compared to placebo, showed a highly significant triglyceride lowering effect in type IV patients (-43% vs. +4%, P less than 0.01), while reducing plasma cholesterol significantly in type II patients (-7% vs. -3%, P less than 0.05). Further reductions in plasma lipids were obtained in both types of hyperlipoproteinemia after the 16-week follow-up. In type II patients, total cholesterol fell by 9% in the former acipimox group and 17% in the former placebo group, whereas a 34% reduction in triglycerides was found in type IV patients previously treated with placebo. Treatment had to be discontinued in 4 patients during the double-blind phase and in 5 patients during follow-up, because of adverse events such as skin reactions and gastric disturbances. Statistical analysis of hematological and biochemical variables expressing safety did not show any significant change during treatment.
Asunto(s)
Hiperlipoproteinemia Tipo II/sangre , Hiperlipoproteinemia Tipo IV/sangre , Hipolipemiantes/farmacología , Lípidos/sangre , Pirazinas/farmacología , Adulto , Anciano , Colesterol/sangre , Ensayos Clínicos como Asunto , Método Doble Ciego , Femenino , Estudios de Seguimiento , Humanos , Hipolipemiantes/efectos adversos , Masculino , Persona de Mediana Edad , Pirazinas/efectos adversos , Triglicéridos/sangreRESUMEN
The effects of two low doses of aspirin (20 mg and 100 mg) on prostacyclin and thromboxane formation during whole blood clotting were studied in 8 healthy volunteers. A single 100 mg aspirin dose caused more than 90% reduction of both serum TXB2 and 6-keto-PGF1 alpha; a single 20 mg dose of aspirin inhibited serum TXB2 more than 6-keto-PGF1 alpha but effects on these two products could not be completely dissociated. However, the effect of a single 20 mg aspirin dose on serum TXB2, was of much longer duration than its inhibitory effect on PGI2 synthesis during whole blood clotting.
Asunto(s)
6-Cetoprostaglandina F1 alfa/biosíntesis , Aspirina/farmacología , Epoprostenol/biosíntesis , Tromboxano B2/biosíntesis , Tromboxanos/biosíntesis , Adulto , Aspirina/administración & dosificación , Coagulación Sanguínea , Inhibidores de la Ciclooxigenasa , Femenino , Humanos , Masculino , Factores de TiempoRESUMEN
In 13 type II hyperlipidemics (10 males and 3 females; mean age 50.2 +/- 10.6 years), in 10 type IV hyperlipidemics (7 males and 3 females; mean age 51 +/- 13.3 years) and in 23 healthy age- and sex-matched controls, the following parameters were measured: plasma cholesterol; plasma TG; plasma C-HDL; VLDL, separated in a preparative ultracentrifuge; C-LDL; Apo B, with immunoelectrophoretic method; platelet sensitivity to prostacyclin; TXB2 formation in PRP; TXB2 in serum. This study provides evidence for: 1. Reduced platelet sensitivity to prostacyclin, more evident in type II hyperlipidemia that provides an additional mechanism involved in increased platelet aggregation found in type II hyperlipidemia. 2. Enhanced TXB2 formation in PRP after thrombin stimulation (664.65 +/- 142.18 pmol/10(8) platelets) only in type II hyperlipidemics and such enhanced formation was positively correlated to C-LDL (r = 0.53; p less than 0.05) and to Apo B (r = 0.62; p less than 0.05); serum TXB2 formation rate was also increased in type II hyperlipidemia.
Asunto(s)
Epoprostenol/farmacología , Hiperlipoproteinemia Tipo II/sangre , Agregación Plaquetaria/efectos de los fármacos , Prostaglandinas/farmacología , Tromboxano B2/farmacología , Tromboxanos/farmacología , Adulto , Anciano , Plaquetas/metabolismo , Colesterol/sangre , Relación Dosis-Respuesta a Droga , Epoprostenol/biosíntesis , Femenino , Humanos , Hiperlipoproteinemia Tipo IV/sangre , Masculino , Persona de Mediana Edad , Tromboxano B2/biosíntesisRESUMEN
Left ventricular hypertrophy (LVH) in hypertensive subjects is associated with an increased prevalence of ventricular arrhythmias. To evaluate the effect of antihypertensive treatment on cardiac arrhythmias (CA) and transient episodes of myocardial ischemia (TEMI), we studied 46 hypertensive patients with LVH, divided into four groups randomly treated with enalapril, hydrochlorothiazide (HCTZ), atenolol, or verapamil (SR-V) for 6 months. Office blood pressure and office heart rate values were recorded, in basal conditions, after 1 and 6 months of treatment, and all patients underwent echocardiography, electrocardiographic Holter monitoring, and stress testing. All drugs significantly lowered blood pressure, whereas left ventricular mass index was reduced by atenolol, enalapril, and SR-V, but not by HCTZ. Treatment induced a significant reduction in the number of patients with supraventricular arrhythmias (35 v 15, P < .034, and 28 v 8, excluding patients treated with HCTZ, P < .008). The number of patients with ventricular arrhythmias was also reduced (32 v 16 considering all groups, P < .08, and 24 v 9, excluding patients treated with HCTZ, P < .04). The number of TEMI during Holter monitoring significantly decreased from 47 to 23 (P = .043) in all patients, and from 39 to 14 (P = .013) excluding patients treated with HCTZ. In all groups, irrespective of treatment, a reduction of blood pressure, heart rate, and systolic blood pressure/heart rate product measured by exercise stress test was observed. The present study shows that in hypertensive patients with LVH, antihypertensive treatment with atenolol, enalapril and SR-V reduces LVH and decreases the prevalence of CA and TEMI. Treatment with HCTZ during the 6-month study did not alter LVH and did not appear to reduce CA and TEMI.
Asunto(s)
Antihipertensivos/administración & dosificación , Arritmias Cardíacas/tratamiento farmacológico , Enalapril/administración & dosificación , Hipertensión/tratamiento farmacológico , Hipertrofia Ventricular Izquierda/tratamiento farmacológico , Isquemia Miocárdica/tratamiento farmacológico , Adulto , Anciano , Antiarrítmicos/administración & dosificación , Arritmias Cardíacas/etiología , Atenolol/administración & dosificación , Presión Sanguínea/efectos de los fármacos , Electrocardiografía Ambulatoria , Femenino , Humanos , Hidroclorotiazida/administración & dosificación , Hipertensión/complicaciones , Hipertrofia Ventricular Izquierda/complicaciones , Masculino , Persona de Mediana Edad , Isquemia Miocárdica/etiología , Resultado del Tratamiento , Verapamilo/administración & dosificaciónRESUMEN
To evaluate the behavior of cardiac arrhythmias (CA) and transient episodes of myocardial ischemia (TEMI), in relation to the circadian pattern of blood pressure in patients suffering from arterial hypertension, with or without echocardiographically ascertained left ventricular hypertrophy (LVH), we studied 128 patients, 87 men (M) and 41 women (F), aging from 21 to 76 years, subdivided into two groups: Group I, including 66 patients with LVH (45 M and 21 F; mean age of 53.7 +/- 9.1 years; Group II, including 62 patients without LVH (42 M and 20 F; mean age of 49.7 +/- 9.5 years). Office blood pressure (OBP) as well as nighttime ambulatory blood pressure (ABP) were higher in patients with LVH (P < .05 and P < .01). CA were present in a higher number of patients of Group I (P < .001): premature supraventricular beats (PSVB) 22.7 v 4.8%, supraventricular couplets (SVC) 36.4 v 16.1%, supraventricular tachycardia runs (SVT runs) 27.3 v 12.9%, ventricular ectopic beats (VEB) 25.6 v 8.0%, ventricular couplets (VC) 30.3 v 12.9%, ventricular tachycardia runs (VT runs) 12.1 v 3.2%. The absolute number of ectopic beats was also significantly higher in patients of Group I. Ventricular arrhythmias were significantly related to ASBP (r = 0.83, P < .01), to ADBP (r = 0.74, P < .01) and to heart rate (r = 0.87, P < .01) in patients of Group I. TEMI were more frequent in patients of Group I (73 v 41 episodes, 39.39% v 25.8% of patients, P < .01) and were related to ABP peaks. In fact, in both groups of patients all TEMI without heart rate increase and most TEMI with heart rate increase were registered between 6:00 and midnight, hours in which ABP values were higher. We conclude that hypertensives with LVH, but without clinical history of coronary heart disease, have a higher prevalence of ventricular arrhythmias and of transient episodes of myocardial ischemia in relation to the circadian pattern of ABP.
Asunto(s)
Arritmias Cardíacas/epidemiología , Arritmias Cardíacas/etiología , Enfermedad Coronaria/complicaciones , Hipertensión/complicaciones , Hipertrofia Ventricular Izquierda/complicaciones , Isquemia Miocárdica/epidemiología , Isquemia Miocárdica/etiología , Adulto , Anciano , Presión Sanguínea/fisiología , Monitoreo Ambulatorio de la Presión Arterial , Ritmo Circadiano/fisiología , Ecocardiografía Doppler , Electrocardiografía , Femenino , Frecuencia Cardíaca/fisiología , Humanos , Masculino , Persona de Mediana EdadRESUMEN
TxB2 formation in PRP after thrombin stimulus, serum TxB2 and platelet sensitivity to prostacyclin and the correlation with ambient fasting plasma glucose and lipoproteins were determined in 20 insulin-independent diabetics (IID) with macroangiopathy, 10 insulin-dependent diabetics (IDD) with microangiopathy and 30 matched controls. Platelets obtained from insulin-independent diabetics synthetize significantly higher amounts of TxB2 than those of insulin-dependent diabetics and matched controls. IDD and IID patients required significantly higher concentrations of prostacyclin (p less than 0.001) for a similar degree of platelet aggregation inhibition. The amount of prostacyclin required for 50% platelet aggregation inhibition was correlated with fasting plasma glucose (r = 0.64, p less than 0.001) and HbA1% (r = 0.48, p less than 0.01) in all diabetic subjects. We conclude that: 1) only PRP, obtained from some insulin-independent diabetics with a concomitant macroangiopathy, shows an increased synthesis of TxB2; 2) platelet sensitivity to prostacyclin is highly dependent on the fasting ambient plasma glucose.
Asunto(s)
Plaquetas/fisiología , Diabetes Mellitus/fisiopatología , Epoprostenol/fisiología , Insulina/fisiología , Prostaglandinas/fisiología , Tromboxano B2/biosíntesis , Tromboxanos/biosíntesis , Adulto , Diabetes Mellitus/metabolismo , Femenino , Prueba de Tolerancia a la Glucosa , Humanos , Lipoproteínas/fisiología , Masculino , Persona de Mediana EdadRESUMEN
The mutagenicity of organic extracts from inhalable airborne particles, collected in a northwestern rural area of Italy in which an industrial plant producing chemical intermediates is present, was assessed during the years 1989 and 1990. The Ames plate test with Salmonella strains TA98 and TA100 with and without metabolic activation was used. Eight sites in the first and three sites in the second year were monitored once and twice a month respectively. Results show that the mutagenicity of air particulate matter reaches maximum values in the cold months and is not dependent on plant activities. In addition, a correlation analysis between mutagenicity data and number of vehicles seems to indicate traffic emissions as the main source of mutagens.
Asunto(s)
Contaminantes Atmosféricos/toxicidad , Monitoreo del Ambiente/métodos , Residuos Industriales/efectos adversos , Mutágenos/toxicidad , Contaminantes Atmosféricos/análisis , Italia , Pruebas de Mutagenicidad , Mutágenos/análisis , Población Rural , Salmonella typhimurium/efectos de los fármacosRESUMEN
The autopsy of a man who died of Hodgkin disease revealed that a peculiar metazoan parasite had proliferated and disseminated throughout his body. The parasite could not be identified; however, electron microscopical studies revealed that it had the structure of a flatworm. This, together with its shape and structure, convinced us that the parasite was an aberrant sparganum manifesting uncontrolled proliferation and dissemination.
Asunto(s)
Cestodos , Infecciones por Cestodos/parasitología , Enfermedad de Hodgkin/parasitología , Terapia de Inmunosupresión/efectos adversos , Plerocercoide , Vasos Sanguíneos/parasitología , Vasos Sanguíneos/ultraestructura , Citoplasma/ultraestructura , Enfermedad de Hodgkin/terapia , Humanos , Masculino , Persona de Mediana Edad , Mutación , Plerocercoide/ultraestructuraRESUMEN
BACKGROUND: Literature concerning exercise-induced platelet activation in chronic stable angina is somewhat confusing. The reason lies in the type of exercise as well as in methodological problems. A powerful, recently introduced procedure to detect platelet activation is flow cytometry. Platelet response to activating factors is mediated by calcium uptake; however, calcium antagonist effect on platelet activity is still unclear. HYPOTHESIS: The study was undertaken to investigate exercise-induced platelet activation before and after treatment with amlodipine in chronic stable angina. METHODS: Twenty patients with chronic stable angina were entered into the study. Each subject underwent a symptom-limited cycloergometer stress test following a washout period of 2 weeks. Blood samples were collected before and immediately after exercise. All subjects were then randomized into two groups of 10 patients each, with Group 1 and Group 2 taking amlodipine 10 mg/day, and placebo for 4 weeks, respectively. They subsequently underwent a second exercise stress test, and blood samples were obtained before and immediately after exercise. Flow-cytometric evaluation of platelet activity was performed in order to recognize GMP-140 expression on platelet membrane. RESULTS: Strenuous exercise induced a significant increase in platelet activation in all subjects prior to therapy. No significant differences were observed in platelet activity at rest between Groups 1 and 2, whereas a significant decrease in exercise-induced platelet activation was demonstrated in Group 1 compared with Group 2. CONCLUSION: Our data provide evidence of the favorable effect of amlodipine on exercise-induced platelet activation in patients affected by chronic stable angina.
Asunto(s)
Amlodipino/uso terapéutico , Angina de Pecho/sangre , Angina de Pecho/tratamiento farmacológico , Bloqueadores de los Canales de Calcio/uso terapéutico , Ejercicio Físico/fisiología , Activación Plaquetaria , Anciano , Amlodipino/farmacología , Angina de Pecho/fisiopatología , Calcio/antagonistas & inhibidores , Bloqueadores de los Canales de Calcio/farmacología , Método Doble Ciego , Prueba de Esfuerzo , Femenino , Citometría de Flujo , Humanos , Masculino , Persona de Mediana Edad , Activación Plaquetaria/efectos de los fármacos , Estadísticas no ParamétricasRESUMEN
Although many data regarding the biosynthesis of thromboxane A2 and prostacyclin in diabetes mellitus have recently appeared in the literature, it is not clear whether an imbalance between the generation of the two prostaglandins might be connected to the vascular complications of diabetes. In the present review we have tried to emphasize the most significant aspects of these studies and we have focused on alterations of platelet prostacyclin receptors and on the effects of circulating immune complexes on platelets of diabetics. It is likely that studies on the release of platelet derived growth factor as well as more precise definitions of its action on vessel wall cells leading to a massive release of prostacyclin, will permit us to ascertain whether an alteration in prostaglandin ratio is linked to the genesis of the vascular complications in diabetics.
Asunto(s)
Plaquetas/fisiología , Angiopatías Diabéticas/etiología , Epoprostenol/sangre , Modelos Biológicos , Tromboxano A2/sangre , 6-Cetoprostaglandina F1 alfa/sangre , Animales , Complejo Antígeno-Anticuerpo/inmunología , Vasos Sanguíneos/fisiopatología , AMP Cíclico/sangre , Diabetes Mellitus Experimental/sangre , Angiopatías Diabéticas/sangre , Angiopatías Diabéticas/inmunología , Endotelio/fisiopatología , Humanos , Agregación Plaquetaria , Factor de Crecimiento Derivado de Plaquetas/fisiología , Receptores de Superficie Celular/fisiología , Receptores de Epoprostenol , Receptores del Factor de Crecimiento Derivado de Plaquetas , Receptores de Prostaglandina/metabolismo , Tromboxano B2/sangreRESUMEN
The effect of a 60 day administration of 200 mg heparan sulfate (Hemovasal 100 b.i.d.) or 100 mg mesoglycan (50 mg b.i.d.) was assessed under double blind design in forty patients (thirty-six males and four females) with peripheral occlusive arterial disease with respect to pain-free walking distance and various haemorheological and haemostasiological variables, platelet aggregation and blood chemistry. The pain-free walking distance significantly improved with heparan sulfate (up 67% from baseline 200.0 +/- 22.5 m and up 34%, with mesoglycan from baseline 207.7 +/- 23.4 m). Heparan sulfate significantly stimulated fibrinolysis and reduced platelet aggregability: these findings suggest an action of heparan sulfate on the endothelial cells, thus reducing their thrombogenicity. The results of the study thus confirm the activity of heparan sulfate in peripheral vascular disease, correcting the conditions which constitute the basis of increased thrombotic risk.